RUBY-1: A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Tolerability of the Novel Oral Factor Xa Inhibitor Darexaban (YM150) Following Acute Coronary Syndrome

Study Questions:

What is the safety, tolerability, and most promising regimen of darexaban (YM150), a novel, oral, direct factor Xa inhibitor, for prevention of ischemic events in acute coronary syndrome (ACS)?